Display options
Cite
Nakaizumi A, Fukumoto M, Kida T, et al. Measurement of serum and vitreous concentrations of anti-type II collagen antibody in diabetic retinopathy. Clin Ophthalmol. 2015;9:543-7doi: 10.2147/OPTH.S75422.
Nakaizumi, A., Fukumoto, M., Kida, T., Suzuki, H., Morishita, S., Satou, T., Oku, H., Ikeda, T., & Nakamura, K. (2015). Measurement of serum and vitreous concentrations of anti-type II collagen antibody in diabetic retinopathy. Clinical ophthalmology (Auckland, N.Z.), 9543-7. https://doi.org/10.2147/OPTH.S75422
Nakaizumi, Atsuko, et al. "Measurement of serum and vitreous concentrations of anti-type II collagen antibody in diabetic retinopathy." Clinical ophthalmology (Auckland, N.Z.) vol. 9 (2015): 543-7. doi: https://doi.org/10.2147/OPTH.S75422
Nakaizumi A, Fukumoto M, Kida T, Suzuki H, Morishita S, Satou T, Oku H, Ikeda T, Nakamura K. Measurement of serum and vitreous concentrations of anti-type II collagen antibody in diabetic retinopathy. Clin Ophthalmol. 2015 Mar 20;9:543-7. doi: 10.2147/OPTH.S75422. eCollection 2015. PMID: 25848204; PMCID: PMC4376299.
Copy Download .nbib Format: NLM
Share it on

Clin Ophthalmol. 2015 Mar 20;9:543-7. doi: 10.2147/OPTH.S75422. eCollection 2015.

Measurement of serum and vitreous concentrations of anti-type II collagen antibody in diabetic retinopathy.

Clinical ophthalmology (Auckland, N.Z.)

Atsuko Nakaizumi, Masanori Fukumoto, Teruyo Kida, Hiroyuki Suzuki, Seita Morishita, Takaki Satou, Hidehiro Oku, Tsunehiko Ikeda, Kimitoshi Nakamura

Affiliations

  1. Department of Ophthalmology, Osaka Medical College, Takatsuki City, Osaka, Japan.
  2. Nakamura Eye Clinic, Nagano, Japan.

PMID: 25848204 PMCID: PMC4376299 DOI: 10.2147/OPTH.S75422

Abstract

BACKGROUND: Autoimmune mechanisms have been postulated as a cause of diabetic retinopathy (DR), as several autoantibodies have reportedly been detected in the serum of DR patients. In this present study, we measured serum and vitreous levels of anti-type II collagen (anti-II-C) antibodies in DR patients and investigated their association with the mechanism of development of DR.

PATIENTS AND METHODS: Blood samples were obtained from patients with proliferative DR and from patients with diabetic macular edema who underwent vitrectomy at Osaka Medical College, Takatsuki City, Osaka, Japan. Diabetic patients without DR were also included. The control group consisted of age- and sex-matched patients with noninflammatory eye diseases who underwent eye surgery for retinal detachment or for cataracts. The levels of anti-II-C immunoglobulin (Ig)G antibody in the vitreous and serum were measured using a human/monkey anti-II-C IgG assay kit.

RESULTS: The serum levels of anti-II-C IgG antibody were significantly higher in the DR patients than in the patients with noninflammatory eye disease (56.8±33.8 units/mL versus 30.5±13.7 units/mL, respectively; P<0.05, Fisher's exact test). These levels were also significantly higher in the diabetic patients without DR than in the patients with noninflammatory eye disease (76.3±49.7 units/mL versus 30.5±13.7 units/mL, respectively; P<0.01, Fisher's exact test). However, anti-II-C IgG antibody levels were unable to be detected in all of the obtained vitreous fluid samples.

CONCLUSION: The development and progression of DR may be related to a mechanism involving intraocular type II collagen, which normally has immunological tolerance as a sequestered antigen. In DR, the disruption of the blood-retinal barrier leads to contact between the intraocular type II collagen and immunocompetent cells, and to subsequent activation of the autoimmune mechanism.

Keywords: autoimmune mechanism; blood–retinal barrier; serum; vitreous

References

  1. Invest Ophthalmol Vis Sci. 2002 Apr;43(4):1104-8 - PubMed
  2. Mediators Inflamm. 2000;9(5):243-8 - PubMed
  3. Science. 1983 Oct 7;222(4619):65-7 - PubMed
  4. Diabetologia. 1978 Mar;14(3):155-8 - PubMed
  5. Med Hypotheses. 2007;68(5):1016-8 - PubMed
  6. Science. 1982 Sep 17;217(4565):1153-5 - PubMed
  7. Zhonghua Nei Ke Za Zhi. 2008 Feb;47(2):125-8 - PubMed
  8. Br J Ophthalmol. 1984 Jan;68(1):10-2 - PubMed
  9. Jpn J Ophthalmol. 2011 May;55(3):256-63 - PubMed
  10. Arthritis Rheum. 1986 Jun;29(6):730-8 - PubMed
  11. J Endocrinol Invest. 2012 Apr;35(4):389-94 - PubMed
  12. Scand J Rheumatol. 1977;6(3):137-43 - PubMed
  13. Ann Otol Rhinol Laryngol. 1992 Dec;101(12):1000-6 - PubMed
  14. J Oral Maxillofac Surg. 1995 Jan;53(1):39-44; discussion 45 - PubMed
  15. Immunology. 2005 Nov;116(3):390-9 - PubMed
  16. Diabetologia. 2005 Jul;48(7):1300-6 - PubMed
  17. Histol Histopathol. 2002;17(3):961-72 - PubMed
  18. Eur J Immunol. 2003 Apr;33(4):1020-9 - PubMed
  19. Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5909-12 - PubMed
  20. Surv Ophthalmol. 1979 Mar-Apr;23(5):279-96 - PubMed
  21. Ann Rheum Dis. 1987 Jul;46(7):534-9 - PubMed
  22. Am J Pathol. 2003 Nov;163(5):1827-37 - PubMed
  23. Ophthalmology. 2012 Jan;119(1):124-31 - PubMed
  24. Arthritis Rheum. 1996 Oct;39(10):1720-7 - PubMed
  25. Ophthalmology. 2005 Nov;112(11):1904-9 - PubMed
  26. Diabetes Res. 1991 Jul;17(3):115-23 - PubMed
  27. Geriatrics. 1973 Jun;28(6):84-91 - PubMed
  28. Diabetologia. 2003 Apr;46(4):511-3 - PubMed
  29. Zhonghua Yan Ke Za Zhi. 2012 Jul;48(7):591-7 - PubMed
  30. Diabetologia. 1992 Sep;35(9):818-27 - PubMed
  31. Retina. 2007 Feb;27(2):211-5 - PubMed
  32. Int Tinnitus J. 2001;7(2):72-83 - PubMed
  33. Acta Otolaryngol Suppl. 1996;522:79-85 - PubMed
  34. Pediatr Diabetes. 2013 Dec;14(8):562-74 - PubMed
  35. Int Rev Immunol. 2002 Mar-Jun;21(2-3):123-52 - PubMed
  36. Vestn Oftalmol. 2000 May-Jun;116(3):31-4 - PubMed
  37. Invest Ophthalmol Vis Sci. 2006 Mar;47(3):1047-55 - PubMed
  38. Int Orthop. 1992;16(3):272-6 - PubMed
  39. Am J Pathol. 1995 Sep;147(3):642-53 - PubMed
  40. Am J Pathol. 1997 Sep;151(3):707-14 - PubMed
  41. Probl Endokrinol (Mosk). 1984 Sep-Oct;30(5):29-34 - PubMed
  42. Retina. 1999;19(5):390-400 - PubMed

Publication Types